Pricing Log in Create free account
Friday 6 November 2026 Export GMED’s income statement to Excel — free account

Globus Medical, Inc.

GMED Healthcare Medical Devices

Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.

Revenue
−0.69%
EPS
+19.3%
Free cash flow
+10.1%

Quarter to September 2026, against a year earlier

70.93 10.51 −12.91%
Market cap
$10.9B
P/E
19.5×
Fwd P/E
18.8×
Dividend yield
—
F-score
9/9
Altman Z
11.30
Beneish M
−2.31
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Globus Medical, Inc. 10-K filed Feb 24, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:08 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 20, 2025: 13 added · 7 removed · 59 modified; 5 with only figures updated

  1. Modified · NuVasive Merger

    On As previously disclosed, on September 1, 2023, pursuant to that certain merger agreement (the “NuVasive Merger Agreement”) with NuVasive, Inc. (“NuVasive”) and Zebra Merger Sub Inc. (“Merger Sub”), Merger Sub, a wholly owned subsidiary of the Company (“Zebra Merger Sub”), Zebra Merger Sub, merged with and into NuVasive, with NuVasive surviving as a wholly owned subsidiary of the Company (the “NuVasive Merger”). Under the NuVasive Merger Agreement, each share of common stock, par value $0.001 per share, of NuVasive issued and outstanding immediately prior to the effective time of the NuVasive Merger (other than certain excluded shares as described in the NuVasive Merger Agreement) was cancelled and converted into the right to receive 0.75 fully paid and non-assessable shares of Class A common stock of Globus, $0.001 par value per share, and the right to receive cash in lieu of fractional shares.